Treatment

Final results from a decade-long National Cancer Institute study show that CD22-targeted CAR T-cell therapy is a highly effective salvage treatment for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL), especially those who relapsed after CD19 therapies. Many relapses occur because leukemia cells lose CD19 expression, a problem called antigen escape. Targeting CD22 […]

The Phase 3 WU-KONG28 trial shows that sunvozertinib (Zegfrovy) is more effective than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. Sunvozertinib significantly delayed cancer growth, offering superior progression-free survival compared with traditional platinum-based chemotherapy. It also outperformed chemotherapy in overall response and disease control rates,

Relapsed B-ALL A post hoc analysis of the Phase 1b/2 FELIX trial shows that obecabtagene autoleucel (obe-cel; Aucatzyl) can provide long-term survival for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), regardless of the type of remission achieved. Patients who reached complete remission (CR) or complete remission with incomplete blood count recovery (CRi)

A study shows that chemotherapy can be safely and effectively given at home through its “Cancer CARE Beyond Walls” program. In this pilot program, a multidisciplinary team delivered 93 intravenous infusions to 10 patients in their homes. The results showed no treatment-related reactions or catheter infections, suggesting the approach is both safe and feasible. The

The National Comprehensive Cancer Network (NCCN) has upgraded its recommendation for nadofaragene firadenovec-vncg to Category 2A for patients with BCG-unresponsive, non-muscle invasive bladder cancer who have high-grade papillary tumors (Ta/T1) without carcinoma in situ (CIS). This aligns the guidance for papillary-only disease with the existing recommendation for patients with CIS. The therapy is FDA-approved for

A recent real-world study confirms that brexucabtagene autoleucel (brexu-cel) is safe and effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), matching results from the pivotal ZUMA-3 trial. The study looked at 292 patients treated between 2021 and 2024 and found similar or slightly lower rates of serious side effects compared to

The combination of enfortumab vedotin and pembrolizumab has reshaped treatment for urothelial cancer, showing strong results across multiple stages of the disease. In metastatic patients, it nearly doubled median overall survival compared to chemotherapy (31.5 vs. 16.1 months). In perioperative settings for cisplatin-ineligible muscle-invasive bladder cancer, it reduced the risk of progression or death by

New results from the ASCO Genitourinary Cancers Symposium highlight advances in renal cell carcinoma (RCC) treatment, focusing on the use of belzutifan. In the adjuvant setting, the LITESPARK-022 trial showed that combining belzutifan with pembrolizumab improved disease-free survival compared with pembrolizumab alone. While high-grade side effects were more frequent, most patients tolerated treatment, suggesting this

The phase 3 LITESPARK-022 trial shows that combining Belzutifan (Welireg) with Pembrolizumab (Keytruda) after surgery significantly lowers the risk of recurrence in patients with high-risk clear cell renal cell carcinoma. The study found a 28% reduction in the risk of recurrence or death compared to Pembrolizumab alone. Overall survival data are still immature, though early

Researchers are testing PMD-026, a new oral drug that blocks RSK, a protein central to cancer cell growth. High RSK levels are found in about 70% of breast cancers and are linked to poor survival and resistance to standard therapies. RSK promotes tumor growth by speeding up the cell cycle, helping cancer cells repair DNA,